Objective: To study cardiovascular disease risk score utility, we compared the association between Framingham Risk Score (FRS)/pooled cohort equation (PCE) categories and coronary artery plaque presence by HIV serostatus and evaluated whether D : A : D risk category more accurately identifies plaque in HIV-infected men.
Introduction
Among HIV-infected individuals, cardiovascular disease (CVD) related mortality is an important cause of death [1, 2] , and epidemiologic studies have shown a greater prevalence of subclinical coronary atherosclerosis among HIV-infected compared with HIV-uninfected individuals [3] [4] [5] . Accurate CVD risk prediction, therefore, is essential for optimal long-term management of HIV-infected persons. CVD risk scores, including the Framingham Risk Score (FRS) and the American College of Cardiology/American Heart Association (ACC/AHA) PCE [6, 7] , predict risk for CVD events and are recommended for use in clinical settings to determine need for preventive therapies, such as lipid-lowering medications. HIV-infected patients have higher FRS than age-matched and sexmatched HIV-uninfected controls due to more smoking and low HDL cholesterol levels [8] . However, FRS has been shown to underestimate cardiac events among HIV-infected persons as their duration of antiretroviral therapy (ART) increased [9] . A low level of agreement between FRS and subclinical atherosclerosis, as measured by carotid intima-media thickness, has been demonstrated among HIV-infected persons, with a large proportion (56.4%) of persons with subclinical atherosclerosis classified as low risk by FRS [10] . This may reflect HIV-related immune activation despite suppressed HIV viremia [11] .
Investigators from the Data Collection on Adverse Effects of Anti-HIV Drugs (D : A : D) group developed an enhanced risk equation that includes HIV-specific factors for use among HIV-infected individuals [12] . The D : A : D score performed better than the FRS in predicting subclinical atherosclerosis measured by intimal-media thickness (IMT) among HIV-infected men; however, about 17% of the HIV-infected patients characterized as low risk by both equations had evidence of atherosclerosis as assessed by IMT [13] . Compared with carotid IMT, presence of coronary artery calcium (CAC) has been shown to improve prediction of incident CVD in the general population [14] . Currently, there is limited data on the associations between cardiovascular disease risk score and subclinical atherosclerosis (including CAC) among individuals with HIV. One study reported a higher FRS among HIV-infected individuals with versus without CAC (mean FRS of 0.19 and 0.12, respectively) [15] .
Our primary objective was to examine the associations of two general population CVD risk scores (the FRS and the ACC/AHA PCE) with the presence of coronary artery plaque among well characterized HIV-infected men and similar at-risk HIV-uninfected men, and whether these associations differ by HIV serostatus.
Methods

Study population
The Multicenter AIDS Cohort Study (MACS) was initiated in 1984 as a study of MSM conducted at four study sites in Baltimore/Washington, District of Columbia, Chicago, Los Angeles, and Pittsburgh. A total of 6972 men have been enrolled over three time periods (1984-1985, 1987-1990, and 2001-2003) , and enrollment is currently open. The details of the study design and methods have been published [16] .
Selection criteria
The analysis included data from a nested CVD computed tomography (CT) scan study, which enrolled 1001 MACS participants who were 40-70 years of age, weighed less than 300 pounds, and had no history of coronary artery revascularization [4] . Only 2% of the sample were missing data on at least one variable required to generate the three risk scores; these participants were excluded from the analytic sample. We also excluded 10 men with adjudicated cardiovascular events (myocardial infarction, stroke, transient ischemic attack, peripheral arterial disease, or nonfatal cardiac arrest) prior to their plaque measurement. The protocol was approved by the Institutional Review Boards at each site, and each study participant signed informed consents.
Plaque outcomes
The details of the CT scanning have been published previously [4, 17] . Briefly, noncontrast cardiac CT scans for CAC and coronary CT angiography (CTA) for other plaque outcomes were performed between January 2010 and August 2013. Men with atrial fibrillation, chronic kidney disease [estimated glomerular filtration rate (GFR) < 60 ml/min per m 2 during a prior MACS study visit], or a history of IV contrast allergy were excluded from CTA studies, and GFR more than 60 ml/min per m 2 was verified within 1 month for those men undergoing CTA. Images from the scans were evaluated at a core CT reading center (Los Angeles Biomedical Research Institute at Harbor-UCLA, Los Angeles, California, USA) by trained and experienced readers who were blinded to participant characteristics, including HIV serostatus. CAC scores were calculated using the Agatston method. For the CTA studies, each segment was analyzed using the modified 15-segment model of the AHA [18] .
Each coronary segment was classified as normal or containing noncalcified plaque, mixed plaque (<50% of plaque area occupied by calcium) or calcified plaque (definitions provided in previous manuscript), and/or stenosis at least 50% [4, 17] . The outcomes for this analysis included the presence of plaque (CAC > 0 on noncontrast CT, and any coronary plaque, noncalcified plaque or mixed plaque on CTA) and coronary artery stenosis at least 50%.
Risk score calculation
For each participant, we calculated the following cardiovascular disease risk scores: the Framingham hard coronary heart disease risk score using code based on the FRS score sheets in the Adult Treatment Panel III (http:// www.nhlbi.nih.gov/files/docs/guidelines/atglance.pdf) [6] , the ACC/AHA PCE [7] , and for HIV-infected participants, the D : A : D score [12] . The participant characteristics that are included in the calculation of each risk score are the risk time horizon, and the outcome(s) predicted by each score are listed (see Table, Supplemental Digital Content 1, which shows each risk score, http://links.lww.com/QAD/A938). Score calculation is described in detail (see Text file, Supplemental Digital Content 2, describing the variables that are included in the risk score, http://links.lww.com/QAD/A938).
For the FRS, individuals with more than 20% estimated risk of MI and coronary death within 10 years are categorized as high risk, persons with 10-20% risk are moderate risk, and persons with less than 10% risk are low risk. All diabetic participants were classified as FRS high risk a priori, regardless of FRS score. The PCE classifies as high risk, individuals with at least 7.5% risk of coronary death or nonfatal MI, or fatal or nonfatal stroke within 10 years; moderate risk for those with 5-7.5% risk; and low risk for those with less than 5% risk. The D : A : D score classifies individuals with more than 10% risk of nonfatal and fatal MI within 5 years as very high risk, 5-10% as high risk, 1-5% as moderate risk, and less than 1% as low risk. We combined the D : A : D very high and high risk categories. Our aim was to compare the extent to which the risk categories used clinically as specified by the various risk algorithms are associated with contemporaneous subclinical coronary disease; therefore, risk categories, rather than risk scores, were our primary predictors.
Statistical analysis
Distributions of demographic, behavioral, and clinical characteristics of HIV-infected and HIV-uninfected men were compared using the chi-square or the Wilcoxon rank sum tests for categorical and continuous variables, respectively.
For each plaque outcome, we fit a logistic regression model using predictors of risk score category and HIV serostatus. Interaction terms were included to evaluate whether the association between risk score category and plaque differed by HIV serostatus. Separate models were run for each general risk score equation (PCE and FRS). Discrimination, the ability of the risk score to classify participants with and without plaque, was assessed separately among HIV-infected and HIV-uninfected men based on the receiver operating characteristic (ROC) curve. The area under the ROC curve was calculated using the trapezoidal rule and was compared by HIV status using a test for two independent samples.
We evaluated the discrimination of the D : A : D score compared with the FRS and PCE among HIV-infected men, using sensitivity and specificity of the risk category cutpoints in addition to the global area under the ROC curve metric. We evaluated the sensitivity and specificity at two thresholds: greater than or equal to the high-risk category and, alternatively, greater than or equal to the moderate-risk categories, for each of the three scores. Sensitivity was the probability of being classified as at least high risk (alternatively ! moderate risk) among men with atherosclerosis. Specificity was the probability of being classified as less than high risk (alternatively < moderate risk) among men without atherosclerosis. We compared the sensitivity and specificity of the algorithms using McNemar's test for dependent samples. The area under the curve was calculated for the thresholds using the trapezoidal rule. As age is a strong determinant of risk score, we stratified the analysis by age greater than 50 to evaluate whether the discrimination metrics differed by age category.
Statistical significance was defined as a P value less than 0.05. All analyses used Stata 13.1 (StataCorp, College Station, Texas, USA). Table 1 shows the distribution of relevant demographic and clinical characteristics by HIV serostatus. The HIVinfected men (n ¼ 599, 61% of sample) were younger and more likely to report being Hispanic/Other or African-American race. The HIV-infected men had higher fasting glucose and were more likely to have diabetes, lower total, HDL cholesterol and LDL cholesterol, higher triglycerides, and lower BMI. The HIV-infected men were more likely to be current smokers and to have hepatitis C virus coinfection.
Results
Demographic and clinical characteristics
Most HIV-infected men (89%) were receiving HAART, median duration of therapy was 9.4 years, and most participants (82%) had undetectable HIV RNA levels. Few were currently taking a regimen that included indinavir, lopinavir, or abacavir (1.0, 8.3, and 4.3%, respectively), antiretroviral drugs in the D : A : D risk score.
Of the 975 participants included in our study sample, all underwent a noncontrast CT (974 noncontrast CT results available; 1 scan was technically limited) for CAC score. Coronary CTA was performed in 749 out of 975 (77% of the total).
The distribution of the risk categories for study participants by HIV serostatus is shown in Fig. 1 , for each CVD risk score algorithm, stratified by age. As expected, men older than 50 years were more likely to be classified as high risk. More HIV-infected compared with uninfected men were classified as high risk in both age groups and across risk algorithms, except for the PCE among men older than 50 years, which categorized twothirds of evaluated men as high risk, regardless of HIV serostatus. Among younger men, the D : A : D risk score classified fewer HIV-infected men as low risk and more as moderate risk compared with the two general population risk categories; it classified fewer as high risk compared with the PCE but more than the FRS for men older than 50 years. Regardless of HIV serostatus, more men were classified as high risk by the PCE.
Association of pooled cohort equation category with coronary plaque by HIV serostatus
We expected that plaque presence would be higher in moderate-risk/high-risk men compared with the lowrisk men, which was generally true ( Table 2) . For example, odds of CAC more than 0 among high-risk HIV-infected men was three times higher than low-risk HIV-infected men [odds ratio (OR) 3.13, P < 0.001]. Odds of CAC more than 0 was even higher among high-risk HIV-uninfected men compared with low-risk HIV-uninfected men [OR of 7.03 (P < 0.001)]. The risk-group-HIV interaction was statistically significant
Similarly, for the presence of any plaque on coronary CTA, mixed plaque, and coronary stenosis at least 50%, we observed higher odds of these outcomes in moderaterisk men compared with low-risk men and in high-risk men compared with low-risk men. Among those outcomes, the high-risk category was more strongly associated with plaque presence among HIV-uninfected compared with HIV-infected men [only statistically significant for mixed plaque (P ¼ 0.04)].
In contrast to other plaque outcomes, the high-risk category was more strongly associated with noncalcified plaque in HIV-infected men compared with HIVuninfected men (OR 3.26, 95% CI 2.08, 5.12 versus 2.09, 95% CI 1.24, 3.52; interaction not significant).
For each plaque outcome, plaque prevalence in the lowrisk group was higher among HIV-infected than HIVuninfected men, though the differences were not statistically significant. For example, 36.0% of low-risk HIV-infected participants had CAC more than 0 compared with 26.5% of low-risk HIV-uninfected men (P value ¼ 0.09) (see PCE, the result of more men being categorized as low risk with the FRS compared with the pooled cohort.
As described in the prior section, the odds of plaque generally increased with increasing PCE risk category, with the OR for the men in the high-risk category greater than the OR for the men in the moderate-risk category. However, the increase in odds with increasing FRS risk category was not as consistent. This is the result of few men being categorized as high risk with the FRS.
When moderate-risk/high-risk category men are considered in a combined fashion for PCE and FRS, odds of plaque are consistently higher compared with low-risk category men.
Again, the associations with noncalcified plaque did not follow the pattern observed with other outcomes. The odds of noncalcified plaque among high-risk HIVinfected men was over three times higher than low-risk HIV-infected men (OR 3.19, P < 0.001). However, the odds of noncalcified plaque among HIV-uninfected men in the high-risk category compared with the low-risk category was 1.39 (P ¼ 0.08) (risk-score-HIV interaction not significant).
We also evaluated the discrimination of the continuous risk scores for the presence of coronary plaque. The ROC curves plot the ability of the scores to separate those with and without coronary plaque (CAC > 0 and stenosis ! 50%) using each observed PCE risk score value as a threshold associated with a sensitivity (y-axis) and 1-specificity (x-axis for CAC > 0) (Fig. 2) . The area under the ROC curve is significantly higher for the HIVuninfected compared with HIV-infected men for CAC more than 0 (0.75 versus 0.65, P < 0.01) and marginally higher for coronary stenosis (0.69 versus 0.59, P ¼ 0.06). Across the range of PCE risk scores for HIV-infected men, a cutpoint with a given level of sensitivity will have worse specificity in the HIV-infected compared with HIV-uninfected men. The ROC curves are similar for the FRS (data not shown). Despite the relative higher performance of the scores among the HIV-uninfected men, the areas under the ROC curve are less than 0.8, a commonly cited threshold for sufficient discrimination, regardless of serostatus.
D : A : D compared with general population cardiovascular disease risk-score categories
Our secondary objective was to evaluate whether the D : A : D score better classified plaque presence than the general population score categories in the HIV-infected men. Table 3 shows that the high-risk category by PCE identified the most men with plaque and stenosis at least 50%, though its specificity was lower than the D : A : D and Framingham. For example, among men aged more than 50 years, the high-risk category included 71.4% of men with CAC more than 0 using the PCE, compared with 40.5% with CAC more than 0 using the D : A : D and just 24.7% with CAC more than 0 using the FRS (P < 0.001 comparing each with pooled cohort). For men aged 50 years or less, the high-risk category captured fewer of those with atherosclerosis for each respective risk equation (e.g. for CAC > 0, sensitivity was 31.8% with the PCE, 17% with FRS, and 15.9% with D : A : D). Conversely, the specificity of the PCE high-risk category was lower compared with D : A : D and FRS (e.g. among men > 50 years old for CAC > 0, 41.1% for pooled cohort, 69.4% for D : A : D, and 74.2% for FRS). The gains in sensitivity when combining the moderate-risk/ high-risk categories are sizeable, particularly for the D : A : D, which classifies the largest proportion of men with plaque as moderate risk, as shown in Fig. 1 . When considering moderate/high as a combined group, the D : A : D has significantly greater sensitivity than the PCE and FRS. None of the risk-score categories had both high sensitivity and specificity, and the area under the curves indicated inadequate discrimination (<70%) of all three scores among HIV-infected men.
The prevalence of any plaque was high among the older HIV-infected men classified as low risk using each of the three scores: 86% (81/94) by FRS, 82% (27/33) by pooled cohort, and 91% (10/11) by D : A : D (see Figure, Supplemental Digital Content 5, http://links.lww.com/ QAD/A938). Despite the similar prevalence across algorithms, the absolute number of men with plaque who are classified as having low risk of cardiovascular outcomes (false negatives), was minimized with the D : A : D, which classifies fewer HIV-infected men as low risk. Among the men aged 50 and younger, the prevalence of any plaque among the men in the lowrisk category was significantly lower in the D : A : D (41%, 19/46) versus the FRS (60%, 86/143) and marginally lower versus the pooled cohort algorithm (58%, 65/113). 
Discussion
In this large, well characterized group of HIV-infected and HIV-uninfected men, moderate and high-risk general population score categories (FRS and PCE) were more strongly associated with plaque presence among HIV-uninfected men than among HIV-infected men. Among HIV-infected men, the PCE high-risk category was more sensitive for plaque presence than both the D : A : D and the FRS; however, the specificity was lower. Current ACC/AHA CVD risk-reduction guidelines recommend statin therapy for patients in the PCE high-risk category, and our results show that for HIVinfected men aged 50 and younger, this will miss most men with plaque and most men with stenosis at least 50%. In both age groups, stenosis at least 50% represents a potentially high-risk lesion that could lead to ischemia. CAC more than 0 is predictive of CVD events compared with CAC ¼ 0 [19] , with the significance of a particular lesion depending on both the degree of CAC and patient's age.
In previous work, FRS and PCE have both been shown to underestimate risk for cardiac events [9, 20, 21] and subclinical atherosclerosis assessed by carotid IMT [10, 13] in HIV-infected persons. The D : A : D score has performed better than general population scores in some studies in predicting myocardial infarction [9] and carotid IMT [13] among HIV-infected people. However, an analysis of HIV Outpatient Study data revealed more observed CVD events than expected by the D : A : D score, with a ratio of expected events to observed events of 0.75. The ratio of expected events to observed events was higher using the FRS (0.85) and the PCE (0.83) [21] . Our study did not show any advantage of the D : A : D score over the general population risk scores for the intermediate outcome of coronary plaque. D : A : D highrisk category was not very sensitive for plaque in either age group examined and when the moderate-risk/highrisk groups were combined (versus the low-risk group); although the sensitivity increased to include almost all of the men with plaque, specificity dropped sharply.
Chronic effects of HIV infection itself (inflammation, hypercoagulability, and endothelial dysfunction), effects of certain ART drugs (hyperlipidemia, insulin resistance), lifestyle risk factors, particularly smoking, and other chronic medical comorbidities (hypertension, diabetes, and hyperlipidemia) [22] [23] [24] [25] contribute to CVD risk among HIV-infected persons. Some factors that contribute to increased risk of CVD among HIV-infected patients (e.g., chronic inflammation) are not incorporated into risk prediction scores [11, 26] . The D : A : D score accounts for certain ART agents (abacavir, indinavir, and lopinavir) that contribute to cardiovascular risk independent of the metabolic derangement expected with any ART [27] [28] [29] [30] . However, this adjustment was of limited importance in our study population with low levels of use of these ART agents. The D : A : D uses an algorithm that weights the effects of traditional risk factors such as age and hypertension based on their associations with cardiovascular outcomes in an HIV-infected rather than the general population. Even so, we did not see an enhanced performance of the D : A : D compared with the general population risk scores in our analysis. Because the upper threshold for the low-risk category (<1% 5-year risk) is so low, few people are classified in the lowrisk group, contributing to the score's low specificity. The strengths of our study include a large sample size with standardized collection of CVD risk factors from which to calculate risk scores and the presence of an HIVuninfected comparison group. We classified subclinical coronary atherosclerosis using coronary CTA, which is a very specific and sensitive measure. Limitations of our study include the cross-sectional analysis and the limited number of hard coronary outcomes, preventing us from looking at associations between risk scores and hard coronary endpoints over time. CVD risk scores were developed to predict hard coronary outcomes, not subclinical CVD, and therefore we might not expect very high discrimination metrics for our intermediate outcomes. However, both CAC and plaque have been associated with subsequent coronary events [19, [31] [32] [33] .
In a large study of outpatients undergoing coronary CTA, cumulative probability of a major coronary endpoint increased with the degree of CAC from 2.1% among individuals with a CAC of 0 to 16.3% among individuals with a CAC more than 400. No plaque was associated with cumulative probability of major adverse cardiac events of 0.8%, and cumulative probability of event increased as the number of involved vessels increased. Calcified plaque had the lowest risk of subsequent event (5.5%), whereas noncalcified and mixed plaque had the highest (22.7 and 37.7%, respectively) [19] . In another study examining plaque characteristics among individuals with acute coronary syndrome, noncalcified plaque presence was two-fold higher comparing acute coronary syndrome (ACS) with non-ACS group members (43 versus 22%, P < 0.01) [33] . There was variation in the prevalence of our plaque outcomes, with mixed plaque and coronary stenosis more than 50% being the least prevalent. Even with the lower prevalence, we observed a stronger risk-score-plaque association for these outcomes among HIV-uninfected men when general population risk scores were used.
In summary, risk-score-plaque associations for the general population risk scores were weaker among HIV-infected men compared with HIV-uninfected men, except for noncalcified plaque. The high-risk category by PCE identified the greatest percentage of men with plaque, regardless of serostatus, however, with very low specificity. No risk score delivered both high sensitivity and specificity among HIV-infected men. Clinicians must balance the limitations of each of the scores, and the risk of side effects with statin therapy, when making individual treatment decisions for their patients.
